Medicus Pharma Ltd. is projected to report a consensus Q3 2026 loss of $8.50 per share on zero revenue, with its current $1.87 share price trading significantly below the $32.50 average analyst target. Investors are primarily focused on the company’s strategic pivot to the Pfizer-partnered CD228V antibody-drug conjugate and terms of the proposed $135 million SPAC merger for its SkinJect subsidiary.
The firm recently executed a 1-for-50 reverse stock split to maintain Nasdaq compliance and faces liquidity risks, reporting only $5.0 million in cash. Shareholders seek updates on Phase 2 clinical timelines and cash runway extension strategies during the upcoming business update call.